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Abstract
Rotavirus is the leading cause of severe diarrhea among children <5 years worldwide. Currently 
licensed rotavirus vaccines have been efficacious and effective, with many countries reporting 
substantial declines in diarrheal and rotavirus-specific morbidity and mortality. However, the full 
public health impact of these vaccines has not been realized. Most countries, including those with 
the highest disease burden, have not yet introduced rotavirus vaccines into their national 
immunization programs. Research activities that may help inform vaccine introduction decisions 
include (1) establishing effectiveness, impact, and safety for rotavirus vaccines in low-income 
settings; (2) identifying potential strategies to improve performance of oral rotavirus vaccines in 
developing countries, such as zinc supplementation; and (3) pursuing alternate approaches to oral 
vaccines, such as parenteral immunization. Policy- and program-level barriers, such as financial 
implications of new vaccine introductions, should be addressed to ensure that countries are able to 
make informed decisions regarding rotavirus vaccine introduction.
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Background
Diarrhea is a major cause of death among children <5 y of age globally.1 Rotavirus is the 
leading cause of severe diarrhea, resulting in an estimated 453 000 deaths in 2008, most of 
which occurred in developing countries of sub-Saharan Africa and South-East Asia (Fig. 
1).2 Rotavirus also causes considerable morbidity, with global estimates of 2.3 million 
hospitalizations and 24 million outpatient visits annually among children aged <5 y.2,3 Data 
from the Global Rotavirus Surveillance Network of the World Health Organization (WHO), 
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a network of sentinel surveillance sites in over 50 countries, indicate that rotavirus is 
responsible for ~40% of acute gastroenteritis hospitalizations among children <5 y of age in 
regions without widespread rotavirus vaccine use.4 Since improvements in water and 
sanitation do not prevent the majority of rotavirus disease, rotavirus vaccines are an essential 
part of an integrated approach to the control of diarrhea that also includes interventions, such 
as access to safe drinking water, sanitation, and handwashing facilities, breast feeding, 
vitamin A and zinc supplementation, and appropriate case management.5 Since 2009, WHO, 
with support from its Strategic Advisory Group of Experts (SAGE) on Immunization, has 
recommended that rotavirus vaccines be included in all national immunization programs and 
considered a priority, particularly in countries with high diarrhea-related mortality.6 By 
April 2014, 56 countries had introduced rotavirus vaccines into their national immunization 
programs, and ~50 more likely will follow within the next several years.7,8
This review will discuss the 2 globally licensed rotavirus vaccines and other vaccines locally 
available or in development, the current status of vaccine introduction, information on the 
impact of vaccine introduction on immunization systems and disease burden, vaccine safety 
issues, and future considerations for vaccine introduction.
Rotavirus Vaccines
Since 2006, 2 rotavirus vaccines have been licensed and used globally—Rotarix 
(GlaxoSmithKline) and RotaTeq (Merck and Co., Inc.). Rotarix is a live, attenuated vaccine 
containing a single G1P[8] human rotavirus strain. RotaTeq is a live, attenuated vaccine 
containing 5 human-bovine reassortant rotavirus strains—G1P7[5], G2P7[5], G3P7[5], 
G4P7[5], and G6P1A[8] (Table 1). Both vaccines are administered orally to infants starting 
at a minimum age of 6 wk, with a minimum 4 wk interval between doses (2 doses per 
Rotarix course, 3 doses per RotaTeq course).6 Previous WHO administration 
recommendations for upper age limits of 15 wk for the first dose of vaccine and 32 wk for 
the last dose of vaccine were removed in 2013.6 For both vaccines, clinical trials conducted 
in high and upper-middle-income countries in the Americas, Asia, and Europe demonstrated 
vaccine efficacy of 72–100% in preventing severe rotavirus disease during 1- to 3-y follow-
up periods, while trials conducted in lower income countries in Africa and Asia 
demonstrated vaccine efficacy of 49–72% (Table 1).9-17 Although definite reasons for this 
lower efficacy are unknown, reasons proposed include factors that can result in interference 
of uptake of a live, oral vaccine, such as breast milk, stomach acid, maternal antibodies, and 
co-administration of oral poliovirus vaccine (OPV), and factors that may cause an impaired 
immune response to vaccine, such as malnutrition, and other infections (e.g., human 
immunodeficiency virus, malaria, and tuberculosis).18,19
China and Vietnam have locally manufactured oral vaccines that are licensed for use only 
within these countries (Table 2). Available in China, the Lanzhou lamb rotavirus vaccine 
(LLR; Lanzhou Institute of Biological Products) is a live, attenuated vaccine containing a 
single G10P[12] lamb rotavirus strain. The recommended schedule of administration is one 
dose annually for children 2 mo to 3 y of age and one dose at age 3–5 y.20 Since 2000, over 
30 million doses have been sold, but little is known about vaccine efficacy, safety, and 
vaccination coverage since LLR is available only through the private market.20 Available in 
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Vietnam, Rotavin-M1 (POLYVAC) is a live, attenuated vaccine containing a single G1P[8] 
human rotavirus strain similar to Rotarix. The recommended schedule of administration is 2 
doses, starting at a minimum age of 6 wk, given at least 30 d apart.21 Phase I and II studies 
demonstrated immunogenicity and safety profiles similar to Rotarix;21 efficacy data 
currently are unavailable. Recently, India licensed its own locally manufactured oral 
vaccine, ROTAVAC (Bharat Biotech International, Ltd) (Table 2). ROTAVAC is a live, 
attenuated vaccine containing a single neonatal rotavirus G9P[11] strain, 116E. The 
recommended schedule of administration is 3 doses at 6, 10, and 14 wk. The phase III trial 
demonstrated vaccine efficacy of ~56% in preventing severe rotavirus diarrhea.22 Bharat 
Biotech is pursuing WHO pre-qualification of the vaccine so that it may be available 
globally.23
Additional live oral and parenteral rotavirus vaccines are in development or clinical trial 
stages, but not yet licensed (Table 2). Five live, single to multi-strain vaccines, including 2 
lamb-human reassortant vaccines from China (Lanzhou and NF-R7), the previously licensed 
rhesus-human reassortant vaccine RotaShield, a bovine-human reassortant vaccine (UK), 
and a neonatal human strain vaccine from Australia (RV3), currently are undergoing clinical 
trials. One subunit rotavirus vaccine currently is undergoing a phase I trial, while several 
other candidates, including an inactivated rotavirus vaccine (IRV), are in pre-clinical stages 
of development. Alternative schedules, such as administration of a neonatal dose 
(RotaShield, RV3) are also being explored.
Current Status of Rotavirus Vaccine Introduction
As of April 2014, 56 countries have introduced rotavirus vaccines into their national 
immunization programs; an additional 4 have introduced vaccines regionally, and 3 have 
widespread coverage through the private market (Fig. 2).7 Although Australia and countries 
in the Americas and Europe were the earliest to introduce after vaccine licensure, countries 
in other regions have followed, many with support from the GAVI Alliance, a public-private 
global health partnership with a mission to save children’s lives and protect people’s health 
by increasing access to immunization in poor countries. As of March 2014, 16 countries 
have GAVI Alliance support to introduce rotavirus vaccines nationally, 4 countries have 
GAVI applications under review, and 11 countries are planning to submit GAVI 
applications.7,8 In addition, 16 non-GAVI eligible countries are planning introductions, 
making a total of 47 more countries planning to introduce rotavirus vaccines within the next 
several years. However, despite this progress and a universal recommendation for inclusion 
of rotavirus vaccines in national immunization programs, 84 countries have no reported 
plans to introduce rotavirus vaccines. The majority (70%) of these countries are located in 
Europe, South-East Asia, and the Western Pacific.
Vaccine Impact
While data from clinical trials provide important information on vaccine efficacy and safety 
in controlled settings, program and field conditions may differ with regards to vaccine 
management and administration and thus impact both vaccine effectiveness and the 
immunization system. Evaluation of the impact of vaccine introduction on immunization 
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systems and disease burden is crucial for improving and sustaining immunization programs 
and stimulating introduction of additional vaccines.
To help evaluate the programmatic impact of new vaccine introduction on immunization 
systems, WHO recommends post introduction evaluations (PIEs) 6–12 mo after any new 
vaccine introduction.24 Findings from these evaluations may provide countries with 
information regarding the impact of rotavirus vaccine introduction on various program 
topics (e.g., vaccination coverage recording and reporting, cold chain and vaccine 
management, monitoring and supervision, training and knowledge of health-care workers, 
waste management, adverse events following immunization, and advocacy and 
communication planning), which may be used to improve local immunization systems and 
inform subsequent vaccine introductions. From 2009–2013, rotavirus vaccine PIEs were 
conducted in 13 countries in Africa, Latin America, the Eastern Mediterranean region, and 
Europe.25
Monitoring of disease trends and vaccine effectiveness studies can provide timely 
information necessary to evaluate the impact of vaccine introduction on disease burden. 
Findings generated from Rotarix and RotaTeq impact assessments, mostly in Australia and 
countries in Europe and the Americas, have demonstrated substantial declines of 22–50% in 
diarrhea-related mortality,26-29 17–55% in diarrhea-related hospitalizations,27,30-45 and 49–
91% in rotavirus-specific hospitalizations among children <5 y of age (Table 
3).30-34,36,37,42-59 Many of these studies also have reported potential indirect benefits for 
unvaccinated older children and young adults, with reductions of 6–51% in diarrhea-related 
hospitalizations30-32,35,37,45,60-62 and 20–92% in rotavirus-specific hospitalizations(Table 
4).31,32,34,37,42-45,49,50,54,56,5,61-63 Additional studies have demonstrated vaccine 
effectiveness in preventing rotavirus hospitalizations similar to vaccine efficacy observed in 
clinical trials. High and upper-middle-income countries including Australia (certain 
regions), Taiwan, Austria, Belgium, France, Germany, Northern Israel, Spain, Mexico, 
Brazil (certain regions), and the US have reported vaccine effectiveness estimates of 79–
100%,37,38,53,60,64-83 while lower income countries including Bolivia, El Salvador, and 
Nicaragua have reported vaccine effectiveness estimates of 43–92% (Table 5).84-89
To date, both Rotarix and RotaTeq have provided protection against a range of rotavirus 
strains, as demonstrated by the Rotarix clinical trials conducted in Africa, for which vaccine 
efficacy was ~60–64% for both G1 (contained in Rotarix) and non-G1 (not contained in 
Rotarix) rotavirus types,90 and by various vaccine effectiveness studies conducted in 
Australia, Europe, and the Americas, for which vaccine effectiveness estimates were 71–
95% against rotavirus strains not contained in RotaTeq and/or Rotarix.38,66,70,78,80,83,89,91 
Monitoring of rotavirus strains continues in order to detect any global changes in strain 
prevalence and any emergence of unusual strains, and allow for strain-specific measures of 
vaccine effectiveness in the event that there is concern about vaccine effectiveness against 
an emergent or novel strain.
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In 1999, the first licensed rotavirus vaccine, RotaShield (Wyeth), was withdrawn from US 
market within a year after licensure due to an association with intussusception, an 
obstruction of the small intestine that can require radiological or surgical intervention. It was 
estimated that ~1 excess case of intussusception occurred per 10 000 infants vaccinated with 
RotaShield.92 Pre-licensure clinical trials for Rotarix and RotaTeq that included 60 000–70 
000 infants each did not demonstrate an increased risk for intussusception,14,16 However, 
post-licensure monitoring studies were recommended to detect a possible low risk that may 
not have been identified in the clinical trials. In 2011, findings from studies conducted in 
Mexico (Rotarix only) and Australia (Rotarix and RotaTeq) reported a low level risk of 
intussusception with both Rotarix and RotaTeq on the order of ~1–2 excess cases per 100 
000 vaccinated infants, mostly within the first week after the first dose of vaccine.93-9 These 
risks were lower than the risk associated with RotaShield, and a subsequent review of 
available data and a risk-benefit analysis of rotavirus vaccination conducted by the WHO 
Global Advisory Committee on Vaccine Safety (GACVS) determined that the benefits of 
rotavirus vaccination of all infants greatly exceeded the risks of intussusception associated 
with vaccination (Table 6).96 Additional analyses to examine the risk-benefit of rotavirus 
vaccination without upper age restrictions estimated that universal rotavirus vaccination in 
low- and low-middle-income countries could prevent an additional 47 200 (range: 18 000–
63 700) rotavirus deaths while potentially causing an additional 294 (range: 161–471) 
intussusception deaths among a cohort of children <5 y of age.98 These analyses contributed 
to the 2013 WHO recommendation that upper age restrictions for rotavirus vaccination be 
removed to allow for greater vaccination coverage and potentially greater reductions in the 
number of rotavirus deaths as the benefits of vaccination continue to outweigh the risks of 
intussusception.6
Recently, new data from the US also have demonstrated a low risk of intussusception with 
both vaccines. In 2 studies conducted among separate managed care populations, an 
approximate risk of 1–5 excess cases of intussusception per 100 000 infants vaccinated with 
rotavirus vaccine was reported.98,99 While the risk-benefit of rotavirus vaccination with 
these 2 vaccines remains approximately the same as that seen when using the earlier risk 
estimates from Mexico and Australia, questions remain as to whether this risk may be higher 
in any particular subgroup of infants and whether the level of risk seen in high- and middle-
income countries will occur in low-income countries where vaccine efficacy is lower.100 
Additional special studies and continued post-introduction intussusception monitoring, 
especially in low-income countries, may help answer these questions.
Future Considerations
Countries worldwide have established estimates of the considerable diarrheal disease burden 
of rotavirus.4,6 Existing licensed rotavirus vaccines have proven to be efficacious in clinical 
trials and effective in post-introduction evaluations, with many countries demonstrating 
adequate capacity to introduce these vaccines into routine immunization programs and 
substantial declines in diarrheal and rotavirus-specific morbidity and mortality (Tables 3-5). 
Despite this, the full public health impact of these vaccines on rotavirus disease and child 
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mortality has not been realized as most countries, including some with the highest disease 
burden, have not yet introduced rotavirus vaccines into their national immunization 
programs. Why is this the case? What are the remaining questions to be answered? What are 
the potential barriers to introduction?
Several key research activities may help to address remaining questions about rotavirus 
vaccine use under field conditions and inform vaccine introduction decisions, especially in 
low-income countries. These include: (1) establishing effectiveness, impact, and post-
licensure safety of the current WHO-prequalified rotavirus vaccines in low-income settings; 
(2) identifying potential strategies to improve performance of oral rotavirus vaccines in 
developing countries, such as zinc supplementation to potentially strengthen the immune 
response to vaccination, withholding breast feeding just before and after vaccine 
administration to prevent interference of vaccine uptake by maternal antibodies, or a 
neonatal dosing schedule to help increase the amount of rotavirus disease prevented in 
settings where children may acquire disease at an earlier age; and (3) pursuing alternate 
approaches to oral vaccines, such as parenteral vaccines to bypass possible interference of 
vaccine uptake by gastric acid and breast milk to improve vaccine efficacy in developing 
countries.18
To identify potential barriers to introduction at a policy level, one may consider key issues 
in the decision-making process to introduce a new vaccine.101 Once barriers are identified, 
solutions may be implemented (Table 7). While each country should have a mechanism for 
an evidence-based, informed-decision making process, which may include expert groups 
that provide technical advice to national immunization programs, such as National 
Immunization Technical Advisory Groups (NITAGs) (http://www.healthinternetwork.com/
immunization/sage/national_advisory_committees/en/) or other advisory committees on 
immunization,101 barriers and concerns may differ by country or even region. For example, 
one country may be concerned with vaccine introduction costs while another may be 
concerned with the programmatic impact of vaccine introduction or vaccine efficacy and 
safety. Given the potential diversity of opinion, it will be crucial to understand issues at the 
local policy making level to best inform decision makers.
During the past several years, significant progress has been made in the prevention and 
control of rotavirus diarrhea. The introduction of rotavirus vaccines into the national 
immunization programs of over 50 countries has resulted in substantial declines in rotavirus-
related morbidity and mortality. However, questions remain that will need to be answered by 
additional research, and policy- and program-level barriers should be removed to ensure that 
countries are able to make informed decisions regarding rotavirus vaccine introduction and 
to help realize the full potential impact of these vaccines.
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Table 1
Currently licensed and globally recommended rotavirus vaccines
Characteristic Rotavirus vaccine
Trade name Rotarix® RotaTeq®
Manufacturer GlaxoSmithKline Merck and Co., Inc.
Country of manufacture Belgium USA
Composition Live-attenuated G1P1A[8] human rotavirus strain
Live human-bovine reassortant rotavirus strains: 
G1P7[5],
G2P7[5], G3P7[5], G4P7[5], G6P1A[8]
Pharmaceutical form Liquid, lyophilized + diluent Liquid
Presentation
1 dose plastic tube or
1 dose applicator or
1 dose vial
1 dose tube
Route of administration Oral Oral
Recommended schedule of
administration
Minimum age of 1st dose: 6 wk
2 doses at least 4 wk apart
Previous WHO recommendations for upper age limits of 15
wk for the first dose and 32 wk for second dose have been
removed
Minimum age of 1st dose: 6 wk
3 doses at least 4 wk apart
Previous recommendations for upper age limits 
of 15 wk for




Hypersensitivity to the active substance or to any of the
excipients; hypersensitivity after previous administration
of rotavirus vaccines; history of intussusception;
history of uncorrected congenital malformation
of the gastrointestinal tract that would predispose
for intussusception; history of severe combined
immunodeficiency disease (SCID)
A demonstrated history of hypersensitivity to 
the vaccine
or any component of the vaccine; history of 
severe
combined immunodeficiency disease (SCID); 
history of
intussusception
Volume per dose 1.5 mL (tube and applicator)1 mL (lyophilized + diluent) 2 mL
Cost per dose GAVI-eligible: $2.43 (2014 UNICEF pricing)Non-GAVI: variable





Mar 2009 (tube and applicator)
Jan 2007 (vial) Oct 2008






97% (88–100) (Hong Kong/Singapore/Taiwan)
2-y follow-up:













Up to 1-y follow-up:
100% (55–100) (Japan)
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Table 2
Rotavirus vaccines that are regionally used, recently licensed, or in development
Name Composition Route ofadministration Organization/Company Stage of development
Lanzhou Lamb
Rotavirus (LLR)




Lanzhou Institute of Biological 
Products,
China
Licensed for use in China
Rotavin-M1
Live attenuated human rotavirus 
strain,
G1P[8]
Oral POLYVAC, Vietnam Licensed for use inVietnam
ROTAVAC Live attenuated neonatal rotavirusstrain, G9P[11] (aka 116E) Oral Bharat Biotech, India
Recently licensed for use





reassortant rotavirus strains, G2, 
G3, G4
Oral






reassortant rotavirus strains, 
tetravalent
Oral International Medica Foundation, USA
Phase II complete,
Phase III pending




reassortant strains, tetravalent to
hexavalent
Oral
National Institutes of Health, 
USA;
Instituto Butantan, Brazil; Serum 
Institute
of India, India; Shantha Biotech, 
India; /
Minghai Biotechnology Co., 
China; Wuhan
Institute of Biological Products, 
China
Phase I and II,
Research
NF-R7 Live attenuated lamb-humanreassortant strain, G4 Oral




Subunit Truncated VP8 of P4, P6, P8 Intramuscular




IRV Inactivated G1P[8], G2P[4] Intramuscular orintradermal
US CDC; multiple (China, 
Europe, India) Pre-clinical
Subunit
Virus-like particles: VP 2/6/7 and 
VP
2/4/6/7
To be determined Baylor College of Medicine, USA Research
Subunit Truncated VP8 in norovirus P particles To be determined




Subunit VP6 combined with norovirusG1 and GII VLPs To be determined
University of Tampere School
of Medicine, Finland Research
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Table 3
Summary of rotavirus vaccine impact studies among children <5 y – disease trends
a
Location Vaccine % Reduction References










Mexico, Nationwide Rotarix 46% 29
Panama, Nationwide Rotarix 32–50% 26
































El Salvador, Nationwide Rotarix 28–37% (includes outpatient) 44
Mexico, Nationwide Rotarix 40% (during rotavirus season) 41
Panama, Bocas del Toro, Chiriquí, Los Santos, San Miguelito, 




• 3 regions (Northeast, Midwest, South)
• Privately insured children, 13 states
b
• New Orleans, LA



















South Africa, Gauteng and Mpmalange provinces Rotarix 32–33% 51
Reduction in rotavirus hospitalizations
Australia
• National
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70% (0 to 1 y)
















Finland, Tampere Rotarix, RotaTeq 91% (<2 y; incl. ER visits) 50
Brazil, Sao Paolo Rotarix 59% 43




• 3 regions (Northeast, Midwest, South)
• Privately insured children, 13 states
b
• Chicago
• Cincinnati, OH, Nashville, TN, Rochester, NY
• Jacksonville, FL
• New Orleans, LA
• New York, NY















62% (during viral season)
55–89% (0 to 35 mo)
72%
67% (includes ED visits)












South Africa, Gauteng and Mpmalange provinces Rotarix 40–44% 52
a
Estimated rotavirus vaccination coverage ranges of 37–94% mostly among children 0–1 y or 0–2 y, if reported.
b
Alaska, Idaho, Massachusetts, Maine, North Dakota, New Hampshire, New Mexico, Oregon, Rhode Island, Vermont, Washington, Wisconsin, 
Wyoming.
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Table 4
Summary of rotavirus vaccine impact studies – indirect benefits for unvaccinated individuals
a
Location Vaccine Age range % Reduction References






2 to 4 y











• New Orleans, LA
• New York, NY
• New York, NY










2 to <5 y
2 to <5 y
5 to 24 y
5 to 44 y
2 to <5 y
2 to <3 y
3 to <5 y
5 to 18 y
35–41%
43–45%






















2 to 19 y










2 to 5 y





Belgium, Nationwide Rotarix, RotaTeq 2 to 5 y 20–64% 42
Finland, Tampere RotaTeq 2 to <16 y 72% 50
Brazil, Sao Paolo Rotarix 2 to <5 y 24% 43







• Cincinnati, OH, Nashville, TN, Rochester, 
NY
• New York, NY
• New York, NY











2 to <5 y
2 to <5 y
5 to 24 y
5 to 44 y
318 y
2 to <3 y
2 to <3 y
3 to <5 y
5 to 18 y
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Location Vaccine Age range % Reduction References
• US military dependents
a
Estimated rotavirus vaccination coverage ranges of 37–94% mostly among children 0–1 y or 0–2 y, if reported.
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Table 5
Vaccine effectiveness (VE) against rotavirus hospitalizations
















Taiwan, Linkou, Changhua, Kaohsiung Rotarix, RotaTeq 92%, 97% G1P[8] 69
Austria, Nationwide Rotarix, RotaTeq 79–96% G1P[8], G2P[4] 53
Belgium, Nationwide Rotarix 90% G2P[4] 67
France, Nortwest Britanny RotaTeq 98% 74
Germany, Mecklenberg-Western Pomerania Rotarix, RotaTeq 80% G1P[8], G9P[8] 64




























El Salvador, Nationwide Rotarix 76% G1P[8] 85
Mexico, Chiapas Rotarix 94% G9P[4] 83
Nicaragua, Nationwide
• Nationwide










64–87% (includes ED 
visits)












• Cincinnati, OH, Nashville, TN, 
Rochester, NY
• Cincinnati, OH, Nashville, TN, 
Rochester, NY
• CA,MO,NY,OH,TN,TX,WA













83–86% (includes ED 
visits)
95%
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Location Vaccine type Vaccine effectiveness Predominant strain References
• CT, GA, MN
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Table 6
Risk of intussusception and benefits of rotavirus vaccination in Mexico, Brazil, Australia, and the US
a
Country Diarrhea hospitalizations (deaths)prevented by vaccination
Intussusception cases (deaths)
potentially caused by vaccination Reference
Mexico 11 600 (663) 41 (2) 94
Brazil 69 600 (640) 55 (3) 94
Australia 7000 (0) 6 (0) 102
US 53 444 (14) 45–213 (0.1–0.5) 103
a
Data are for one fully vaccinated birth cohort followed to age 5 y.













Yen et al. Page 26
Table 7
Key issues and potential barriers and related questions in the decision to introduce rotavirus vaccine





Competing priorities (e.g., other
new vaccine introductions, other
health interventions on the public
health agenda)
Do policy makers have sufficient
information to appropriately
prioritize rotavirus vaccine?
Ensure that existing disease 
burden
and vaccine information and
impact data available to policy
makers
Evidence of disease burden
• Lack of local disease 
burden data
• Lack of regional 
disease burden data
• Is the local rotavirus 
disease burden similar 
to other countries?
• What is the rotavirus 
disease burden in other 
countries in the 
region?
• Establish sentinel 
rotavirus surveillance
• Communicate with 
regional partners to 
share available 
disease burden data
Vaccine efficacy, quality and 
safety
• Lack of local efficacy/
effectiveness data
• Concerns about 
intussusception
• Will the current 
vaccines be able to 
provide protection 
against the local 
rotavirus strains?
• Why is vaccine 
efficacy worse in 
lower income 
countries?
• Will vaccine use be 








• Investigate strategies 
to improve vaccine 
uptake











Existing interventions to 
prevent
rotavirus
Lack of awareness regarding the
role of rotavirus vaccine as the 
main
means of prevention
Won’t improve access to clean
water and sanitation prevent
rotavirus disease?
Improve communication about
the role of rotavirus vaccines as
the current mainstay for rotavirus
prevention





• High cost of existing 
rotavirus vaccines
• Lack of cost-related 
analyses
• Will rotavirus vaccines 
ever be sold at a lower 
price?
• What is the potential 
cost-effectiveness of a 
rotavirus vaccination 
program?
• What is the potential 
fiscal impact of 
rotavirus vaccine 
introduction on the 
immunization 
program?











Vaccine packaging will take up 
too
much cold chain space
Is there sufficient cold chain
capacity for rotavirus vaccines? If
not, how can we increase 
capacity?
Support cold chain assessments
(i.e., Effective Vaccine 
Management)
and expansion as needed
Vaccine supply availability Available vaccine supply Will there be enough vaccine Work with vaccine manufacturers
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Key issues Potential barriers/concerns Related questions Potential solutions
insufficient to accommodate
national introduction
supply for the country’s target
population?
to ensure sufficient global 
vaccine
supply
Strength of the existing
immunization program
Current routine immunization
program not ready to introduce
a new vaccine (e.g., insufficient
capacity to accommodate
new vaccine, insufficient
resources - funding and/or staff
- to conduct training sessions
and social mobilization)
How will we be able to
acquire the resources and





including potential means for
acquiring necessary funding
Hum Vaccin Immunother. Author manuscript; available in PMC 2016 January 19.
